FibroGen shares skid lower as a surprise adcomm raises risks on roxa OK
FibroGen will likely have to delay its US rollout for roxadustat once again.
In an unexpected move, the FDA is convening its Cardiovascular and Renal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
